You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1626 Results
Document
Jul 2025
Document
Jul 2025
Document
Jul 2025
Document
Jul 2025
Document
Jul 2025
Document
Jul 2025
Document
Jul 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
DOCEtaxel,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2025
Guidelines and Advice
Status: Current
Aug 2025
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative, Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Primary Advanced or Recurrent Endometrial Carcinoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
PACLitaxel,
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Curative
Drugs Used:
durvalumab (Compassionate),
gemcitabine,
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Drugs Used:
pembrolizumab (Unfunded),
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025

Pages